DISCOVERY OF A NOVEL BCP-ALL MOLECULAR SUBGROUP DEFINED BY IGH::FENDRR GENE FUSION, FOXF1 OVEREXPRESSION AND KRAS A146 MUTATION

EHA Library, Sonja Bendig, 4160412

DNMT3A LIMITS MYELOID SIGNALING RESPONSES IN T-CELL PROGENITORS DURING NORMAL AND LEUKEMIC DEVELOPMENT

EHA Library, Marissa Foo, 4160413

SENSITISATION AND ERADICATION OF DRUG-RESISTANT PAEDIATRIC ETP-ALL BY REPURPOSING DECITABINE

EHA Library, Yizhou Huang, 4160422

CLUSTERING ANALYSIS OF ALTERNATIVE SPLICING IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IDENTIFIED TARGETABLE SUBTYPE WITH GLOBAL SPLICING DEFECTS

EHA Library, Margaret Heung-Ling Ng, 4160424

NOTCH1 TRANSLOCATIONS DEFINE A SPECIFIC SUBTYPE OF HIGH-RISK CORTICAL TYPE T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA

EHA Library, Martina Lucarelli, 4160426

SMARCC1 CONTROLS THE ONCOGENIC NOTCH1 TRANSCRIPTIONAL PROGRAM IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Khalid Shoumariyeh, 4160427

BCR::ABL1 BALANCES CELLULAR DEMAND AND SUPPLY BY JOINTLY ENGAGING STAT5 SIGNALING AND GLYCOLYTIC METABOLISM DOWNSTREAM OF INTERLEUKIN 7 RECEPTOR IN MURINE PREB CELLS

EHA Library, Dennis Das Gupta, 4160429

TARGETING ONCOGENE-INDUCED SENESCENCE IN ETV6::RUNX1 PRE-LEUKEMIC CELLS

EHA Library, Mayla Bertagna, 4160430

INDUCTION OF ONTOGENY-SPECIFIC PRE-LEUKEMIC STEM CELLS IN A KMT2A::AFF1 MURINE MODEL

EHA Library, Ariana Calderón, 4160431

THERAPEUTIC EFFICACY OF BIOMIMETIC NANODRUG CX4945 IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Yan Wang, 4160432

ALLOGENEIC TRANSPLANTATION OUTCOMES OF MDS/AML: RISK VERIFICATION AND MATCHED ANALYSIS WITH AML—A MULTICENTER STUDY

EHA Library, Yuhua Ru, 4160702

OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR SECONDARY MYELODYSPLASTIC SYNDROME EVOLVED FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Machiko Fujioka, 4160704

A PHASE I DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF F182112, BCMA X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, mingyuan Sun, 4160705

SPECTRUM, PREVALENCE AND CLINICAL CORRELATES OF PPM1D MUTATIONS IN PATIENTS WITH THERAPY RELATED CLONAL HEMATOPOIESIS AND CLONAL CYTOPENIAS

EHA Library, Talha Badar, 4160710

A PHASE I OPEN LABEL STUDY OF FOSTAMATINIB, A SYK INHIBITOR, IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Jennifer Croden, 4160712

PHASE I/II TRIAL OF AZACITIDINE AND VENETOCLAX IN PREVIOUSLY UNTREATED AND HYPOMETHYLATING AGENT FAILURE MYELODYSPLASTIC SYNDROME: AN INTERIM EFFICACY ANALYSIS

EHA Library, Ian Bouligny, 4160713

HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH IMETELSTAT IN THE IMERGE TRIAL

EHA Library, María Díez Campelo, 4160714

THERAPEUTIC INTERVENTION IN BONE MARROW FAILURES: TARGETING NUCLEOLAR AND RIBOSOME STRESS INDUCED BY HNRNPK OVEREXPRESSION

EHA Library, Miguel Gallardo, 4160717

ACCURATE QUANTIFICATION OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE IN NEUTROPHILS: ADDED VALUE OF ANTI-CD16 ANTIBODY IN ELIMINATING EOSINOPHIL CONTAMINATION

EHA Library, Bouchra BADAOUI, 4160724

HETROMBOPAG COMBINED WITH CYCLOSPORINE A AS FIRST-LINE TREATMENT IN PATIENTS WITH NON-SEVERE APLASTIC ANEMIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY

EHA Library, Xin Zhao, 4160726

DANICOPAN ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS STRATIFIED BY BONE MARROW FAILURE HISTORY

EHA Library, Morag Griffin, 4160727

BUSULFAN, LOW DOSE CYCLOPHOSPHAMIDE, AND FLUDARABINE VERSUS BUSULFAN PLUS STANDARD-DOSE CYCLOPHOSPHAMIDE CONDITIONING REGIMEN IN HAPLOIDENTICAL CELL TRANSPLANTATION FOR PATIENTS WITH ACQUIRED APLASTIC ANEMIA: A PROPENSITY SCORE MATCHED CONTROLLED STUDY.

EHA Library, Fan Lin, 4160728

EVALUATING THE SAFETY AND EFFICACY OF MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH CHRONIC NEUTROPENIC DISORDERS: RESULTS FROM THE PHASE 2 STUDY

EHA Library, Julia Warren, 4160729

IMMUNE-DRIVEN SELECTION AND FREQUENT DETECTION OF PNH CLONES IN POST-CAR-T THERAPY HEMATOPOIETIC FAILURE

EHA Library, Yuki Nukii, 4160734

COMPARISON OF OF HETROMBOPAG VERSUS ELTROMBOPAG COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORINE A AS FIRST-LINE THERAPY FOR SEVERE APLASTIC ANEMIA: SIMILAR EFFICACY AND SAFETY

EHA Library, Jingnan Sun, 4160735

DUAL PLATFORM GENOMIC TESTING FROM DIRECT SKIN BIOPSY FOR DETECTION OF GERMLINE PREDISPOSITION IN BONE MARROW FAILURE AND HEMATOLOGIC MALIGNANCY

EHA Library, Enrico Attardi, 4160736

A BENEFIT ASSESSMENT OF PEGCETACOPLAN DOSE INCREASE IN THE PHASE 3 PEGASUS TRIAL OF PNH PATIENTS WITH DIFFICULT-TO-CONTROL DISEASE

EHA Library, Morag Griffin, 4160737

THE STOCKHOLM NEUTROPENIA STUDY - COMPARISONS OF PATIENTS WITH IDIOPATHIC OR AUTOIMMUNE NEUTROPENIAS

EHA Library, Henric Lindqvist, 4160741

MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, ALLOWS FOR GRANULOCYTE-COLONY STIMULATING FACTOR DOSE DE-ESCALATION IN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA AND CONGENITAL NEUTROPENIA

EHA Library, Julia Warren, 4160744

ANELLOVIRUS-ASSOCIATED SUBOPTIMAL HEMATOLOGICAL RECOVERY IN SEVERE APLASTIC ANEMIA AFTER IMMUNOSUPPRESSIVE THERAPY

EHA Library, Guangsheng He, 4160745

MEZIGDOMIDE (MEZI) IN NOVEL COMBINATIONS EFFECTIVELY REACTIVATES IMMUNE SYSTEM IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) INCLUDING THOSE AFTER T-CELL-REDIRECTING THERAPIES

EHA Library, Luciano J. Costa, 4160749

MOLECULAR INSIGHTS INTO MULTIPLE MYELOMA BONE DISEASE: SINGLE-NUCLEUS RNA-SEQ ANALYSIS OF OSTEOCLAST DIFFERENTIATION

EHA Library, Melika Bakharzi, 4160750

CAR-T CELL BASED ON STEM CELL-LIKE MEMORY T CELL ENHANCES ANTI-TUMOUR EFFECT ON MULTIPLE MYELOMA

EHA Library, Zhaoyun Liu, 4160752

A NOVEL PEPTIDE-BASED PROTAC SELECTIVELY TARGETING NUCLEUS EXPORT PROTEIN XPO1 FOR MULTIPLE MYELOMA THERAPY

EHA Library, Yi Liu, 4160754

CREB1 GLOBALLY REGULATES OXIDATIVE STRESS AND PROTEOTOXICITY IN MULTIPLE MYELOMA

EHA Library, Francesca Cottini, 4160756

IMMUNOMMAP: INSIGHTS INTO IMMUNE AND GENOMIC ALTERATIONS UNDERLYING THE RESISTANCE TO BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA BY FULL SPECTRUM CYTOMETRY AND EXOME SEQUENCING

EHA Library, Daniel Bilek, 4160758

BELANTAMAB MAFODOTIN TREATMENT TRIGGERS IMMUNOLOGIC AND INFLAMMATORY CELL DEATH IN MYELOMA, WITH IMPLICATIONS FOR THE TUMOUR MICROENVIRONMENT AND DURATION OF RESPONSE.

EHA Library, Edmund Watson, 4160760

MECHANISM OF BUTYRATE-REMODELED FATTY ACID OXIDATION IN NK CELLS IN THE TREATMENT OF MULTIPLE MYELOMA WITH DARATUMUMAB

EHA Library, Tingting Li, 4160761

ROLE AND MECHANISM OF PIM-2 KINASE INHIBITOR-INDUCED IMMUNOGENIC CELL DEATH IN MULTIPLE MYELOMA

EHA Library, Hongli Shen, 4160762

ACQUIRED PYRIDOXAL PHOSPHATE (VITAMIN B6) DEFICIENCY AS MECHANISM FOR NEUROPATHY IN POEMS SYNDROME

EHA Library, Oliver Tomkins, 4160763

INCREASING TUMOR DENSITIES ARE ASSOCIATED WITH REMODELING OF THE BONE MARROW MYELOID AND STROMAL MICROENVIRONMENT IN NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Marnix Koops, 4160764

COMPLEMENT AND AMYLOID SIGNATURE PROTEIN UPREGULATION IN POST- TREATMENT AL AMYLOID PROTEOMES PROVIDES NOVEL INSIGHTS INTO DISEASE BIOLOGY

EHA Library, Matthew Rees, 4160765

IMAGE-BASED EX-VIVO IMMUNOTHERAPY SCREENING ASSAY PREDICTS RESPONSE TO BISPECIFIC T CELL ENGAGERS IN MULTIPLE MYELOMA PATIENTS

EHA Library, Frederik Herzberg, 4160767

DIRECT TARGETING ONCOGENIC RAS ON LEUKEMIC CELLS WITH BI-SPECIFIC PCC ANTIBODIES NOT RESTRICTED TO THE HLA SYSTEM

EHA Library, Thomas Bumm, 4160768

DI-(2-ETHYLHEXYL) PHTHALATE (DEHP) AND ITS METABOLITE PROMOTE MULTIPLE MYELOMA PROGRESSION AND BORTEZOMIB RESISTANCE

EHA Library, Wenxia Li, 4160771

IMPAIRED BONE MARROW AND CIRCULATING γΔ T CELLS WERE LINKED TO AN INCREASED RISK OF PROGRESSING FROM PRE-MALIGNANT PLASMA CELL CONDITIONS TO SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Anna Maria Corsale, 4160773

CREB-BINDING PROTEIN (CBP) DEFICIENCY IN THE EARLY B CELL COMPARTMENT IMPAIRS IMMUNE RESPONSES AND ALTERS GUT MICROBIOME DYNAMICS DURING CHRONIC VIRAL INFECTION

EHA Library, Zhe Lu, 4160414

DRUG-RESPONSE MODULATING GENES IN ETV6::RUNX1 CHILDHOOD LEUKEMIA

EHA Library, Laura Oksa, 4160415

CAPTURE PROFILING REVEALS AGE-RELATED IG/TR PROFILES, MUTATIONAL PATTERNS AND CLONAL HAEMATOPOIESIS SIGNATURES IN ADULT PATIENTS WITH ALL

EHA Library, Cecilia Bozzetti, 4160416

EFFICACY OF NOVEL TARGETED THERAPIES IN DOWN SYNDROME ACUTE LYMPHOBLASTIC LEUKAEMIA

EHA Library, Kunjal Panchal, 4160417

TARGETING POLYAMINES IN PEDIATRIC TCF3::PBX1 B-ALL

EHA Library, James Kim, 4160418

ANTIBIOTIC-RELATED MICROBIOME DYSBIOSIS DAMPENS HEMATOLOGIC RECOVERY AFTER CD19 CAR-T CELL INFUSION

EHA Library, Jiachen Liu, 4160419

DEEP MOLECULAR PROFILING REVEALS PROGNOSTIC MARKERS FOR REFINED PATIENT STRATIFICATION AND TARGETABLE ALTERATIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Borbála Péterffy, 4160420

L-ASPARAGINASE ALTERS REDOX HOMEOSTASIS IN ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Matus Kolarik, 4160423

ROLE OF TP53 MUTATIONS IN REFINING PROGNOSIS OF KTM2A-REARRANGED ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

EHA Library, Mariangela Di Trani, 4160425

CD49F, A USEFUL MRD AND SUPPOSED PREDICTIVE MARKER OF LATE RELAPSE IN PEDIATRIC B-ALL

EHA Library, Gábor Barna, 4160428

CHEMORESISTANT ALL CELL LINES EXHIBIT REDUCED MITOCHONDRIAL DAMAGE AND INCREASED MITOCHONDRIAL BIOGENESIS UPON CHEMOTHERAPY.

EHA Library, Jenny Chatzigerou, 4160434

MUSASHI-2 PROMOTES CHEMOTHERAPY RESISTANCE OF INFANT KMT2A-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA VIA REGULATING THE BIOENERGETIC METABOLISM.

EHA Library, Luigia Valsecchi, 4160435

MOLECULAR DETERMINANTS OF SENSITIVITY AND RESISTANCE TO A NOVEL AKR1C3-ACTIVATED PRODRUG IN PEDIATRIC LEUKEMIA

EHA Library, Faezeh Khalili, 4160436

THE EXPRESSION AND FUNCTION OF NINJURIN2 IN ACUTE T-LYMPHOID LEUKEMIA

EHA Library, Hongxia Chen, 4160437

WHOLE TRANSCRIPTOME SEQUENCING UNCOVERS KEY CODING AND NON-CODING BIOMARKERS IN IKZF1PLUS B-ALL

EHA Library, Gadha Krishna Leons, 4160438

RISK FACTORS OF PROGRESSION TO MYELOFIBROSIS IN PATIENTS WITH MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS WITH SF3B1 MUTATION AND THROMBOCYTOSIS

EHA Library, Fuhui Li, 4160701

A PHASE 2 PROSPECTIVE STUDY EVALUATING LOW-DOSE DEFERASIROX IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROME RESISTANT OR RELAPSING AFTER ERYTHROPOIETIN STIMULATING AGENTS (LODEFI)

EHA Library, Mathieu Meunier, 4160703

A PHASE 2, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF OB756, A NOVEL JAK2 INHIBITOR, IN JAK INHIBITOR-NAÏVE PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Library, Jian Huang, 4160706

UPSTAGED RISK FROM THE REVISED TO THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM PREDICTS ADVERSE OUTCOMES IN MYELODYSPLASTIC SYNDROMES

EHA Library, Alexandre Bazinet, 4160707

TP53 MUTATIONS DISTINGUISH A CLASS OF HIGHLY HOMOGENOUS MYELOID NEOPLASMS WITHIN MDS AND AML IN THE CONTEXT OF COMPLEX KARYOTYPE

EHA Library, Ye Yang, 4160708

ASSESSING AVAILABLE RISK SCORES FOR DISEASE PROGRESSION AND SURVIVAL IN CCUS: A SINGLE-INSTITUTION STUDY

EHA Library, Aref Al-Kali, 4160709

PHASE 2 RANDOMISED TRIAL, REPURPOSING DANAZOL AND VBAP IN LOW RISK MYELODYSPLASTIC SYNDROME: REPAIR-MDS

EHA Library, Manoj Raghavan, 4160711

OUTCOMES WITH IMETELSTAT BY SERUM ERYTHROPOIETIN LEVELS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES WHO WERE TREATMENT NAIVE OR WHO HAD PRIOR TREATMENT WITH ERYTHROPOIESIS-STIMULATING AGENTS

EHA Library, Rami S. Komrokji, 4160715

VALIDATION OF MASP-3 AS A NOVEL PROXIMAL TARGET FOR COMPLEMENT-MEDIATED DISEASES: LEARNINGS FROM NONCLINICAL AND CLINICAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) STUDIES

EHA Library, W. Jason Cummings, 4160716

METABOLIC DYSREGULATION IN ERCC6L2 DISEASE: IMPLICATIONS FOR ERYTHROPOIESIS THROUGH GLUTAMINE, GLUTATHIONE, AND FERROPTOSIS PATHWAYS

EHA Library, Ilse Kaaja, 4160718

SOMATIC PRE-MALIGNANT CLONES IN THE ORAL MUCOSA OF FANCONI ANEMIA PATIENTS, WITH AND WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Tamar Berger, 4160719

NOVEL TOOLS TO DISCOVER THE CELLULAR SOURCES OF GENOTOXIC FORMALDEHYDE THAT DRIVES FANCONI ANEMIA

EHA Library, Brandon James, 4160720

BOTH RARE PNH CELLS AND MINOR PNH CLONES SHOULD BE CONSIDERED AS GENUINE PNH CLONES: INSIGHTS FROM ANALYSIS OF THE 5-YEAR FRENCH NATION-WIDE MULTICENTER OBSERVATIONAL STUDY

EHA Library, Orianne Wagner-Ballon, 4160721

THE ROLE OF CD8+CD28-REGULATORY T CELLS IN ACQUIRED APLASTIC ANEMIA

EHA Library, Meili Ge, 4160722

THE SUBGROUP OF APLASTIC ANEMIA PATIENTS IS CHARACTERIZED BY IMPAIRED MESENCHYMAL STROMAL CELLS PROLIFERATION AND ADIPOGENIC DIFFERENTIATION

EHA Library, Alena Dorofeeva, 4160723

ANALYSIS OF THE RECOVERY OF IMMUNE STATUS IN THE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AFTER TREATMENT WITH COMPLEMENT C5 INHIBITOR

EHA Library, Rong Fu, 4160725

CLINICAL AND GENETIC CHARACTERISTICS OF A LARGE COHORT OF PEDIATRIC PATIENTS WITH SHWACHMAN-DIAMOND SYNDROME (SDS)

EHA Library, Ekaterina Deordieva, 4160730

CYCLOPHOSPHAMIDE COMBINED WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IMPROVES EARLY RESPONSE RATES IN SEVERE APLASTIC ANEMIA: A PHASE II CLINICAL TRIAL

EHA Library, Hong Pan, 4160731

THE SURVIVAL ADVANTAGE OF REDUCED-TOXICITY CONDITIONING WITH BUSULFAN/FLUDARABINE/LOW-DOSE CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH PRE-TRANSPLANT COMORBIDITIES.

EHA Library, Fan Lin, 4160732

SPECTRUM AND PREVALENCE OF NON-HEMATOLOGICAL MALIGNANCIES IN PATIENTS WITH TELOMERE BIOLOGY DISORDERS

EHA Library, Madeline Franke, 4160733

IMPACT OF FRONT-LINE ALLOGENEIC HSCT OR IMMUNOSUPPRESSIVE THERAPY ON SURVIVAL IN APLASTIC ANEMIA PATIENTS

EHA Library, Alfadil Haroon, 4160738

MOLECULAR AND CLINICAL FEATURES OF ACQUIRED APLASTIC ANEMIA WITH DDX41 MUTATIONS

EHA Library, Xin Zhao, 4160739

BENEFIT OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IRRESPECTIVE OF BASELINE TRANSFUSION STATUS

EHA Library, Britta Höchsmann, 4160740

LONG-TERM OUTCOMES OF ELTROMBOPAG TREATMENT IN FANCONI ANEMIA PATIENTS WITH BONE MARROW DYSFUNCTION: EXTENDED FOLLOW-UP FROM THE FANCREV TRIAL

EHA Library, Guzmán López de Hontanar Torres, 4160742

CHARACTERISTICS OF HEMATOLOGICAL DISORDERS IN SHORT TELOMERE SYNDROMES

EHA Library, Inés Zugasti, 4160743

PROPHYLAXIS AND MANAGEMENT OF THROMBOEMBOLISM IN PNH PATIENTS: AN ITALIAN SURVEY

EHA Library, Anna Paola Iori, 4160746

NEW CONSENSUS RISK DEFINITION PREDICTS OUTCOMES WITH DARATUMUMAB-BASED QUADRUPLET REGIMENS FOR MULTIPLE MYELOMA

EHA Library, Kylee Maclachlan, 4160747

SELECTIVE DEPLETION OF B-CELL LINEAGE SUBSETS DURING TREATMENT WITH ANTI-BCMA VS ANTI-GPRC5D BISPECIFIC ANTIBODIES (BSABS) UNDERLIES DIFFERENT RISK OF INFECTIONS IN PATIENTS WITH MULTIPLE MYELOMA (MM)

EHA Library, Tomas Jelinek, 4160748

ZMYND8 READS H3K36ME2 TO ACTIVATE CEBPE TRANSCRIPTION AND SUPPRESS MULTIPLE MYELOMA PROGRESSION THROUGH THE INHIBITION OF ADAPTIVE UPR PATHWAYS

EHA Library, Bing Chen, 4160751

CCR4 MODULATES MALIGNANT PROGRESSION OF MULTIPLE MYELOMA VIA PI3K/AKT/MTOR SIGNALING AXIS: MECHANISTIC INSIGHTS AND TARGETED THERAPEUTIC STRATEGY

EHA Library, Yonghuai Feng, 4160753

HP-001, AN ORAL IKZF 1/3 MOLECULAR GLUE, DEMONSTRATED SUPERIOR DEGRADATION POTENCY AND SPECIFITY IN THE PRE-CLINICAL MODEL

EHA Library, Dihuang Wang, 4160755

THE MECHANISM OF EXOSOMAL CIRC-G042080 PROMOTING MYELOMA BONE DISEASE THROUGH MIR-6791-3P/HDAC4/RANKL AXIS

EHA Library, Xing Cui, 4160757

EPIGENETIC DRIVERS OF IMMUNOTHERAPY RESISTANCE IN MULTIPLE MYELOMA: ADVANCED MULTI-OMIC PROFILING IDENTIFIES BCMA AND FCRL5 SILENCING VIA LONG-RANGE DNA HYPERMETHYLATION

EHA Library, Larissa Haertle, 4160759

THE IMMUNOMODULATORY EFFECTS OF DARATUMUMAB-BASED THERAPY ON FUNCTIONAL HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA (FHRMM) PATIENTS ENROLLED IN THE MYDRUG OBSERVATIONAL TRIAL

EHA Library, Chaitanya Acharya, 4160766

PAEONIFLORIN INHIBITS THE ANGIOGENESIS OF MULTIPLE MYELOMA VIA DECREASING MEF2A LEVEL TO DOWNREGULATE THE EXPRESSION OF EXOSOMAL LNCRNA MALAT1

EHA Library, Xing Cui, 4160769

IDENTIFICATION OF TRANSLOCATION-INDUCED ENHANCER HIJACKING IN MULTIPLE MYELOMA BY TRANSFINDER

EHA Library, Jin Lu, 4160770

GENOMIC LANDSCAPE OF PARA-SKELETAL AND EXTRAMEDULLARY PLASMACYTOMAS IN MULTIPLE MYELOMA PATIENTS

EHA Library, Martin Stork, 4160772

DEFINING A NOVEL CYTOKINE COMBINATION TO OPTIMIZE IN VITRO CULTURE CONDITIONS FOR PRIMARY MULTIPLE MYELOMA PATIENT CELLS

EHA Library, Ariene Cabantog, 4160774

THE BIOLOGICAL RELEVANCE OF UPREGULATED NONO PROTEIN IN MULTIPLE MYELOMA THROUGH THE REGULATION OF CELL CYCLE PROGRESSION AND DRUG TREATMENT RESPONSE

EHA Library, Giuseppina Fabbiano, 4160775